Challenges and Opportunities for the Use of Medications to Treat Opioid Addiction in the United States and Other Nations of the World

Journal of Addictive Diseases

Volumn 34, Issue 2-3, 2015, Pages 255-262

  Parrino, Mark W ^a   Maremmani, Angelo Giovanni Icro ^b   Samuels, Paul N ^c   Maremmani, Icro ^d  

^a American Association for the Treatment of Opioid Dependence   (United States)

^b UNIVERSITY OF PISA   (Italy)

^c Legal Action Center   (United States)

^d UNIVERSITY OF PISA   (Italy)

Author keywords

heroin addiction; Medication assisted treatment; prescription opioid abuse

Indexed keywords

DIAMORPHINE; DRUGS USED IN THE TREATMENT OF ADDICTION; BUPRENORPHINE; METHADONE; NALTREXONE; NARCOTIC AGENT; NARCOTIC ANTAGONIST;

ARTICLE; CLINICAL SUPERVISION; CRIMINAL JUSTICE; DRUG DEPENDENCE TREATMENT; HEALTH CARE ACCESS; HEALTH CARE POLICY; HEROIN DEPENDENCE; HUMAN; INTERNATIONAL COOPERATION; METHADONE TREATMENT; OPIATE ADDICTION; PUBLIC HEALTH SERVICE; STRATEGIC PLANNING; UNITED STATES; BEHAVIOR, ADDICTIVE; DRUG MISUSE; HEALTH; HEALTH CARE DELIVERY; LEGISLATION AND JURISPRUDENCE; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PROCEDURES;

BEHAVIOR, ADDICTIVE; BUPRENORPHINE; GLOBAL HEALTH; HEALTH SERVICES ACCESSIBILITY; HUMANS; METHADONE; NALTREXONE; NARCOTIC ANTAGONISTS; NARCOTICS; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PRESCRIPTION DRUG MISUSE; UNITED STATES;

EID: 84940189501     PISSN: 10550887     EISSN: 15450848     Source Type: Journal    
DOI: 10.1080/10550887.2015.1059113     Document Type: Article

References (20)

1. Paulozzi LJ, Budnitz DS, Xi Y. Increasing deaths from opioid analgesics in the United States. Pharmacoepidem Dr S 2006; 15 (9):618-27.
2. Cicero TJ, Inciardi JA, Munoz A. Trends of abuse in OxyContin and other opioid analgesics in the United States: 2002-2004. J Pain 2005; 6(10), 662-72.
3. SAMHSA. Results from the 2012 National Survey on Drug Abuse and Health: Summary of National Findings. NSDUH Series H-46, Publication No. (SMA) 13-4795. Center for Behavioral Health and Statistics Quality. U. S. Department of Health and Human Services. Rockville, MD, 2013.
4. ONDCP (Office of National Drug Control Policy). National drug control strategy. Washington, DC: Legal Action Center, 2014.
5. Legal Action Center. Legality of denying access to medication assisted treatment in the criminal justice system. New York: United States Department of Justice, 2011.
6. BJA (Bureau of Justice Assistance), U. S. Department of Justice. (2013). Residential substance abuse treatment (RSAT) training tool: medication assisted treatment for offender populations. Washington, DC: United States Department of Health and Human Services, 2013.
7. SAMHSA (Substance Abuse and Mental Health Services Administration). Einstein expert panel: medication-assisted treatment in the criminal justice system, 2013b, Rockville, MD. Retrieved on September 10, 2013, from http://www. samhsa. gov/ sites/default/files/mat-criminal-justicepanel-2011. pdf
8. NADCP (National Association of Drug Court Professionals). Adult drug court best practice standards, 1. Alexandria, VA: National Association of Drug Court Professionals, 2013.
9. Maremmani AGI, Rovai L, Pani PP, et al. Do methadone and buprenorphine have the same impact on psychopathological symptoms of heroin addicts? Ann Gen Psychiatry 2011; 10:17.
10. Colasanti A, Rabiner EA, Lingford-Hughes A, Nutt DJ. Opioids and anxiety. J Psychopharmacol 2011; 25:1415-33.
11. Berrocoso E, Sanchez-Blazquez P, Garzon J, Mico JA. Opiates as antidepressants. Curr Pharm Des 2009; 15:1612-22.
12. Deltito J, Maremmani I. The promise of opioid receptor antagonist drugs in the treatment of neuropsychiatric disorders. Heroin Addict Relat Clin Probl 2001; 3: 7-12.
13. Emrich HM. Endorphins in psychiatry. Psychiatr Dev 1984; 2:97-114.
14. Gold MS, Pottash ALC, Sweeney DR, Martin D, Extein I. Antimanic, antidepressant, and antipanic effects of opiate: clinical, neuro-anatomical, and biochemical evidence. Ann NY Acad Sci 1982; 398: 140-50.
15. Maremmani AGI, Pani PP, Rovai L, et al. The effects of agonist opioids on the psychopathology of opioid dependence. Heroin Addict Relat Clin Probl 2013; 15: 47-56.
16. Maremmani I, Pacini M, Pani PP, Parrino M. Say "yes" to methadone and buprenorphine in Russian federation. Heroin Addict Relat Clin Probl 2006; 8:5-22.
17. Maremmani I, Pacini M, Lubrano S, Giuntoli G, Lovrecic M. Harm reduction and specific treatments for heroin addiction. Different approaches or levels of intervention? An illness-centered perspective. Heroin Addict Relat Clin Probl 2002; 4:5-11.
18. Joseph, H. In the service of patients: the legacy of Dr. Dole. Heroin Addict Relat Clin Probl 2006; 8:9-28.
19. Ulmer A, Lamy D, Reisinger M, Haraldsen M, Maremmani I, Newman R. How should methadone-and buprenorphine-treatment be organized and regulated? A comparison of two systems in the context of an Europad-conference in Brussels. Heroin Addict Relat Clin Probl 2012; 14:5-10.
20. Maremmani I, Barra M, Burton-Phillips E, et al. The Italian Manifesto for the treatment of heroin addiction. The mixed care model. A proposed layout for a new healthcare system for citizens with heroin addiction. Heroin Addict Relat Clin Probl 2013; 15:63-78.